Compare Smith & Nephew plc (SNN) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Invesco S&P 500 Momentum ETF — how do they compare? Smith & Nephew plc trades at $30.05 (market cap $12.54B), while Invesco S&P 500 Momentum ETF trades at $151.2. The key difference: Smith & Nephew plc pays a 2.65% dividend while Invesco S&P 500 Momentum ETF pays none, and Invesco S&P 500 Momentum ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| SNN | SPMO | |
|---|---|---|
Market Cap | $12.54B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $38.70 | $161.66 |
52-Week Low | $28.73 | $107.84 |
Enterprise Value | $15.57B | — |
Dividend Yield | 2.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNN trades at $29.87, down 0.71% on the day, with a bearish technical signal. The company reported Q2 2026 revenue growth of 1.6%, below expectations, leading to a reduced full-year outlook. Fundamentals show improvement with 2025 revenue of $6.16B and net income of $625M, yielding a 10.08% margin, though recent earnings have been mixed. The balance sheet remains solid with $619M in cash and a debt-to-asset ratio of 29.75% for 2025.
The outlook is cautious due to near-term operational weakness, particularly in U.S. Orthopaedics, offset by innovation in robotics and wound care. Risks include execution challenges and competitive pressures, while analyst sentiment is predominantly Hold. The stock's valuation appears reasonable with a P/E of 20.41, but growth catalysts are needed for significant upside.
SPMO is trading at $151.21, up 1.69% with strong momentum characteristics. The ETF has demonstrated significant outperformance versus the S&P 500, gaining 26% year-to-date according to 24/7 Wall Street (2026-07-20). Technical indicators show a bullish trend with support at $147-148 and resistance at $149-151, though RSI levels suggest potential near-term consolidation.
The momentum-focused strategy continues to deliver alpha through concentrated technology exposure, particularly AI beneficiaries. However, high concentration risk and sector rotation vulnerability present challenges. With institutional interest growing and momentum factor dominance persisting, SPMO offers strategic exposure to market leaders but requires monitoring for momentum shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →
